Αποτελέσματα Αναζήτησης
10 Ιουλ 2023 · Mechanism of Action. Clopidogrel is an irreversible inhibitor of the platelet P2Y12 adenosine diphosphate receptor. Inhibition of this receptor prevents the downstream activation of the glycoprotein IIb/IIIa receptor complex, which leads to reduced platelet aggregation.
Clopidogrel is a prodrug of a platelet inhibitor that irreversibly binds to P2Y 12 ADP receptors and prevents platelet aggregation. Learn about its indications, interactions, metabolism, and more from DrugBank, a comprehensive drug database.
Clopidogrel is a thienopyridine that irreversibly inhibits the P2Y12 receptor on platelets, reducing the risk of heart disease and stroke. Learn about its medical uses, side effects, interactions, pharmacokinetics, and pharmacogenetics.
17 Φεβ 2020 · Clopidogrel is an antiplatelet agent that requires biotransformation to an active metabolite that blocks P2Y12 receptors on platelets. Learn about its dosage, onset of action, half-life, use in specific populations, and labeled and off-label indications.
The antiaggregating properties of this compound are well known and, very recently, new results have clarified its mechanism of action. Clopidogrel is active only after intravenous or oral administration, and no circulating activity has been found in the plasma of treated animals or human volunteers.
Its active form (Act-Met) is produced by metabolism of the prodrug through the cytochrome P450 system of the liver, most particularly by the enzyme CYP2C19. Act-Met permanently and irreversibly disables the G protein−coupled platelet receptor known as P2Y12.
7 Νοε 2022 · Antiplatelet medications are divided into oral and parenteral agents. Oral agents subdivide further based on the mechanism of action. Aspirin was the first antiplatelet medication and is a cyclooxygenase inhibitor. Other oral antiplatelet agents include clopidogrel, ticagrelor, prasugrel, pentoxifylline, cilostazol, and dipyridamole.
